Part 7-2 (Psychotropic Medications) Flashcards
Psychotropic Medications
Sedative hypnotics
Anti-anxiety drugs
Antipsychotics
Treatment of dementia
Psychosis
Much more severe form of mental illness than depression
Psychosis cause
Increased dopamine activity in specific CNS pathways
Other NTs may be involved (Seratonin, Glutamate, ACh)
Antipsychotics characteristics
Block CNS dopamine receptors, especially D2 receptors
Common antipsychotics
Classified as traditional vs newer “atypical” agents
Atypical agents may be preferred d/t fewer/milder effects
Traditional antipsychotic examples
Chlorpromazine (Thorazine)
Haloperidol (Haldol)
Prochlorperazine (Compazine)
Atypical antipsychotic examples
Clozapine (Clozaril)
Risperidone (Risperdal)
Olanzapine (Zyprexa)
Quetiapine (Seroquel)
Atypical antipsychotic characteristics
Weak blockers of D2 receptors
Strong blockers of serotonin receptors
-Normally better tolerated
Traditional Antipsychotic adverse effects
Orthostatic hypotension Sedation Anticholinergic effects (Inc. HR, GI problems, dry throat)
Atypical antipsychotic adverse effects
Weight gains
Increased blood lipids
Increased gluten sensitivity
Primary concern of all antipsychotics
Extrapyramidal (motor) side effects
Extrapyramidal side effects
Tardive Dyskinesia (Oral facial movements)
Pseudoparkinsonism
Akathisia
Other dystonias/dyskinesias
Tardive Dyskinesia
25% of patients on long term traditional antipsychotics
Cause: Denervation supersensitivity (post-synaptic neuron makes more receptors)
Can be permanent
Tardive Dyskinesia best treatment
Early recognition and change in type or dose of drug.
Tardive Dyskinesia Risk factors
Advanced age Genetic predisposition Affective mood disorders Diabetus Mellitus Hx of alcohol abuse >6 months continuous use of antipsychotic
Neuroleptic Malignant syndrome
Can occur with all antipsychotics
- Catatonia, rigidity, tremors, fever
- increased risk if high dose, agitated patient, impaired mental function
- Can be fatal; need to detect early
Dementia
Irreversible dementia: Alzheimer disease
Degenerative changes in neuronal structure and function
Goals of drug therapy in dementia
Improve cognitive and intellectual function
Improve/modify behavior
Improving cognitive function
Neuronal changes lead to decreased ACh activity in brain
Cholinergic stimulants: increased ACh activity
Indirect Cholinergic stimulants: dementia
Drug inhibits cholinesterase enzyme
ACh breakdown is inhibited
ACh activity/effects are prolonged
Use in early stages when brain still produces ACh
Cholinergic stimulants in Alzheimer
Donepezil (Aricept)
Galantamine (Razadyne)
Rivastigmine (Exelon)
Tacrine (Cognex)
Memantine (Namenda)
Blocks NMDA-glutamate receptors in brain
Normalizes glutamate influence
Slows progression; may be combined with traditional
Drugs used to improve or modify behavior
Antidepressents
Antianxiety drugs
Antipsychotics
Behavior modification in Alzheimer’s
Government regulations curb use of antipsychotics
More emphasis on using symptom-specific meds
Consider nonpharmacologic interventions